13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001773195
Total reported value
$2.2B
$2.2B
91 檔
19.4%
At the close of Q1 2025, Affinity Asset Advisors, LLC disclosed equity holdings valued at approximately $2.2B, spread across 91 reported holdings.
In Q1 2025, Affinity Asset Advisors, LLC displayed an active expansion posture, initiating 91 new positions and adding to 0 existing holdings, outstripping position reductions.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | SPY | Ss Spdr S&p 500 ETF Trust-us | ETF-Large Cap & Growth | 22.96% | -6.72% | EXIT | |
| 2 | IWM | Ishares Russell 2000 ETF | ETF-Small Cap | 5.71% | — | — | |
| 3 | XENE | Xenon Pharmaceuticals Inc | Stock-Other | 4.25% | -0.68% | +14.38% | |
| 4 | APGE | Apogee Therapeutics Inc | Stock-Other | 4.10% | +0.33% | +23.56% | |
| 5 | XBI | Ss Spdr S&p Biotech ETF | ETF-Tech | 3.87% | — | -33.33% | |
| 6 | VRNA | Verona Pharma PLC - Adr | Stock-Other | 3.73% | — | -6.82% | |
| 7 | ACLXGBX | Arcellx Inc | Stock-Other | 3.32% | -2.15% | EXIT | |
| 8 | ALKS | Alkermes plc | Stock-Healthcare | 3.15% | +0.79% | -9.09% | |
| 9 | NUVL | Nuvalent Inc-a | Stock-Other | 3.11% | -0.05% | +61.40% | |
| 10 | PTGX | Protagonist Therapeutics Inc | Stock-Other | 2.64% | +0.01% | +340.38% | |
| 11 | MDGL | Madrigal Pharmaceuticals Inc | Stock-Healthcare | 2.53% | -0.52% | -3.03% | |
| 12 | 260 | Centessa Pharmaceuticals-adr | Stock-Other | 2.12% | -2.87% | EXIT | |
| 13 | AMGN | Amgen Inc | Stock-Healthcare | 2.08% | — | +133.33% | |
| 14 | TEVA | Teva Pharmaceutical-sp Adr | Stock-Healthcare | 2.05% | -1.61% | — | |
| 15 | MLYS | Mineralys Therapeutics Inc | Stock-Other | 1.97% | -0.14% | +271.43% | |
| 16 | TVTX | Travere Therapeutics Inc | Stock-Other | 1.83% | +0.31% | +435.00% | |
| 17 | VERA | Vera Therapeutics Inc | Stock-Other | 1.42% | -0.04% | +45.92% | |
| 18 | ALNY | Alnylam Pharmaceuticals Inc | Stock-Healthcare | 1.42% | — | — | |
| 19 | WVE | Wave Life Sciences Ltd. | Stock-Other | 1.41% | -0.52% | EXIT | |
| 20 | OMER 5.25 02-15-26Bond | Omeros CORP | Bond | 1.36% | — | — | |
| 21 | ✓ | Merus N V | Stock-Other | 1.29% | — | -17.28% | |
| 22 | AXSM | Axsome Therapeutics Inc | Stock-Healthcare | 1.11% | — | +33.33% | |
| 23 | KPTI 3 10-15-25Bond | Karyopharm Therapeutics | Bond | 1.11% | — | — | |
| 24 | ✓ | Establishment Labs Holdings In | Stock-Other | 1.09% | +0.28% | +0.20% | |
| 25 | INSM | Insmed Inc | Stock-Healthcare | 1.02% | -0.92% | +180.00% | |
| 26 | BBIO | Bridgebio Pharma Inc | Stock-Healthcare | 0.99% | -0.58% | EXIT | |
| 27 | NAMS | NewAmsterdam Pharma Company N.V. | Stock-Other | 0.98% | -0.03% | +17.60% | |
| 28 | NRIX | Nurix Therapeutics Inc | Stock-Other | 0.92% | +0.29% | -13.77% | |
| 29 | CORT | Corcept Therapeutics Inc | Stock-Healthcare | 0.76% | -0.10% | EXIT | |
| 30 | TRVI | Trevi Therapeutics Inc | Stock-Other | 0.75% | +0.29% | — | |
| 31 | SYRE | Spyre Therapeutics Inc | Stock-Other | 0.74% | +1.80% | -41.57% | |
| 32 | IMVT | Immunovant Inc | Stock-Other | 0.70% | +0.04% | +330.00% | |
| 33 | TVTX 2.25 03-01-29Bond | Travere Therapeutics Inc | Bond | 0.67% | — | +16.67% | |
| 34 | ORKA | Oruka Therapeutics Inc | Stock-Other | 0.53% | +1.27% | +47.92% | |
| 35 | NBIX | Neurocrine Biosciences Inc | Stock-Healthcare | 0.53% | — | — | |
| 36 | AVTX | Avalo Therapeutics Inc | Stock-Other | 0.50% | +1.39% | +19.32% | |
| 37 | VRDN | Viridian Therapeutics Inc | Stock-Other | 0.50% | -0.04% | +144.34% | |
| 38 | LXEO | Lexeo Therapeutics Inc | Stock-Other | 0.49% | -0.28% | — | |
| 39 | CRNX | Crinetics Pharmaceuticals In | Stock-Other | 0.49% | -0.01% | -66.90% | |
| 40 | EXEL | Exelixis Inc | Stock-Healthcare | 0.48% | — | — | |
| 41 | RZLT | Rezolute Inc | Stock-Other | 0.47% | — | +7.94% | |
| 42 | CATX | Perspective Therapeutics Inc | Stock-Other | 0.45% | -0.03% | +71.09% | |
| 43 | AUTL | Autolus Therapeutics PLC | Stock-Other | 0.45% | — | -32.33% | |
| 44 | ERAS | Erasca Inc | Stock-Other | 0.44% | -0.12% | +33.69% | |
| 45 | EWTX | Edgewise Therapeutics Inc | Stock-Other | 0.42% | — | — | |
| 46 | ✓ | Proqr Therapeutics N.v. | Stock-Other | 0.42% | +0.26% | +16.27% | |
| 47 | QURE | uniQure N.V. | Stock-Other | 0.40% | +0.53% | — | |
| 48 | ✓ | Stock-Other | 0.35% | — | — | ||
| 49 | SLNOEUR | Soleno Therapeutics Inc | Stock-Other | 0.34% | — | -61.60% | |
| 50 | ✓ | Inozyme Pharma Inc | Stock-Other | 0.34% | — | -2.63% |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | SPY | Ss Spdr S&p 500 ETF Trust-us | — | NEW | New buy |
| 2 | IWM | Ishares Russell 2000 ETF | — | NEW | New buy |
| 3 | XENE | Xenon Pharmaceuticals Inc | — | NEW | New buy |
| 4 | APGE | Apogee Therapeutics Inc | — | NEW | New buy |
| 5 | XBI | Ss Spdr S&p Biotech ETF | — | NEW | New buy |
| 6 | VRNA | Verona Pharma PLC - Adr | — | NEW | New buy |
| 7 | ACLXGBX | Arcellx Inc | — | NEW | New buy |
| 8 | ALKS | Alkermes plc | — | NEW | New buy |
| 9 | NUVL | Nuvalent Inc-a | — | NEW | New buy |
| 10 | PTGX | Protagonist Therapeutics Inc | — | NEW | New buy |
| 11 | MDGL | Madrigal Pharmaceuticals Inc | — | NEW | New buy |
| 12 | 260 | Centessa Pharmaceuticals-adr | — | NEW | New buy |
| 13 | AMGN | Amgen Inc | — | NEW | New buy |
| 14 | TEVA | Teva Pharmaceutical-sp Adr | — | NEW | New buy |
| 15 | MLYS | Mineralys Therapeutics Inc | — | NEW | New buy |
| 16 | TVTX | Travere Therapeutics Inc | — | NEW | New buy |
| 17 | VERA | Vera Therapeutics Inc | — | NEW | New buy |
| 18 | ALNY | Alnylam Pharmaceuticals Inc | — | NEW | New buy |
| 19 | WVE | Wave Life Sciences Ltd. | — | NEW | New buy |
| 20 | OMER 5.25 02-15-26Bond | Omeros CORP | — | NEW | New buy |
| 21 | ✓ | Merus N V | — | NEW | New buy |
| 22 | AXSM | Axsome Therapeutics Inc | — | NEW | New buy |
| 23 | KPTI 3 10-15-25Bond | Karyopharm Therapeutics | — | NEW | New buy |
| 24 | ✓ | Establishment Labs Holdings In | — | NEW | New buy |
| 25 | INSM | Insmed Inc | — | NEW | New buy |
| 26 | BBIO | Bridgebio Pharma Inc | — | NEW | New buy |
| 27 | NAMS | NewAmsterdam Pharma Company N.V. | — | NEW | New buy |
| 28 | NRIX | Nurix Therapeutics Inc | — | NEW | New buy |
| 29 | CORT | Corcept Therapeutics Inc | — | NEW | New buy |
| 30 | TRVI | Trevi Therapeutics Inc | — | NEW | New buy |
| 31 | SYRE | Spyre Therapeutics Inc | — | NEW | New buy |
| 32 | IMVT | Immunovant Inc | — | NEW | New buy |
| 33 | TVTX 2.25 03-01-29Bond | Travere Therapeutics Inc | — | NEW | New buy |
| 34 | ORKA | Oruka Therapeutics Inc | — | NEW | New buy |
| 35 | NBIX | Neurocrine Biosciences Inc | — | NEW | New buy |
| 36 | AVTX | Avalo Therapeutics Inc | — | NEW | New buy |
| 37 | VRDN | Viridian Therapeutics Inc | — | NEW | New buy |
| 38 | LXEO | Lexeo Therapeutics Inc | — | NEW | New buy |
| 39 | CRNX | Crinetics Pharmaceuticals In | — | NEW | New buy |
| 40 | EXEL | Exelixis Inc | — | NEW | New buy |
| 41 | RZLT | Rezolute Inc | — | NEW | New buy |
| 42 | CATX | Perspective Therapeutics Inc | — | NEW | New buy |
| 43 | AUTL | Autolus Therapeutics PLC | — | NEW | New buy |
| 44 | ERAS | Erasca Inc | — | NEW | New buy |
| 45 | EWTX | Edgewise Therapeutics Inc | — | NEW | New buy |
| 46 | ✓ | Proqr Therapeutics N.v. | — | NEW | New buy |
| 47 | QURE | uniQure N.V. | — | NEW | New buy |
| 48 | ✓ | — | NEW | New buy | |
| 49 | SLNOEUR | Soleno Therapeutics Inc | — | NEW | New buy |
| 50 | ✓ | Inozyme Pharma Inc | — | NEW | New buy |
According to official SEC Form 13F filings, Affinity Asset Advisors, LLC reported a total U.S. public equity portfolio value of $2.2B across 91 disclosed positions in Q1 2025.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including SPY, IWM, XENE) accounted for 19.4% of total reported equity market value during Q1 2025.
Top New Position Initiated
SPY
市值: $240.5M
During Q1 2025, Affinity Asset Advisors, LLC's top holdings by market value included SPY (23.0%)、IWM (5.7%)、XENE (4.3%). The largest single position, SPY, represented 23.0% of total portfolio value.
In Q1 2025, Affinity Asset Advisors, LLC made 91 total portfolio adjustments, initiating 91 new buys, adding to 0 positions, trimming 0 holdings, and fully liquidating 0 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.